Chardan announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), raising aggregate gross proceeds of approximately $70.0 million. LogicBio began trading on the NASDAQ Capital Market on October 19, 2018.
NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), raising aggregate gross proceeds of approximately $70.0 million. LogicBio began trading on the NASDAQ Capital Market on October 19, 2018.
Chardan has participated in advisory and capital raising transactions totaling more than $2 billion in 2018.
About Chardan
Chardan is an independent global investment bank specializing in healthcare, SPACs and emerging growth companies. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc.
Learn more about Chardan: www.chardan.com
Media Contact:
Emily Levine, Chardan
elevine@chardan.com
(646) 465-9018
Tom Rozycki, Prosek Partners
trozycki@prosek.com
(646) 503-5657
View original content:http://www.prnewswire.com/news-releases/chardan-serves-as-lead-manager-for-logicbio-therapeutics-300735489.html
SOURCE Chardan Capital Markets, LLC
Company Codes: NASDAQ-NMS:LOGC
